Literature DB >> 9557715

A virus with a mutation in the ICP4-binding site in the L/ST promoter of herpes simplex virus type 1, but not a virus with a mutation in open reading frame P, exhibits cell-type-specific expression of gamma(1)34.5 transcripts and latency-associated transcripts.

L Y Lee1, P A Schaffer.   

Abstract

The herpes simplex virus type 1 L/S junction-spanning transcripts (L/STs) are a family of multisized transcripts expressed at high levels in cells infected with mutant viruses that (i) do not express ICP4, (ii) specify forms of ICP4 unable to bind to the consensus ICP4 binding site, or (iii) contain mutations in the ICP4 binding site located at the transcriptional start site of the L/STs. By extension, the failure to detect the L/STs in wild-type virus-infected cells is due to the repressive effect of ICP4 bound to its cognate binding site upstream of the L/ST transcription initiation site. ORF-P, the first and largest open reading frame (ORF) encoded by the L/STs, overlaps >90% of the ORF encoding ORF-34.5, a putative neurovirulence factor, which is transcribed from the opposite DNA strand. Viruses with mutations in the overlapping region of ORF-P and ICP34.5 exhibit premature shutoff of infected-cell protein synthesis and are highly attenuated following intracranial inoculation of juvenile mice. To determine whether the premature protein shutoff and neuroattenuated phenotypes of ORF-P ORF-34.5 double mutants are a consequence of alterations in ORF-P, ORF-34.5, or both, viruses containing mutations only in ORF-P or only in the ICP4 binding site in the L/ST promoter were isolated and characterized. Mutant virus L/ST-n38 contains a single-base-pair transition mutation in ORF-P codon 38, resulting in translational termination of the ORF-P protein (OPP). This mutation does not alter the amino acid sequence of ICP34.5. Expression of a truncated form of OPP by mutant virus L/ST-n38 did not result in premature shutoff of infected-cell protein synthesis and produced no other observable phenotype relative to wild-type virus in in vitro tests. Moreover, the 50% lethal dose (LD50) of L/ST-n38 was comparable to that of wild-type virus following intracranial inoculation of 3-week-old mice, as were the latency and reactivation phenotypes of the virus. These properties of L/ST-n38 indicate that the attenuated phenotype of ORF-P ORF-34.5 double mutants is a consequence of mutations that affect the function of ICP34.5 and not the function of OPP. Mutant virus LST-4BS contains four single-base-pair substitutions in the ICP4 binding site in the L/ST promoter that abrogate the binding of ICP4 to this site, leading to high-level expression of the L/STs and OPP. LST-4BS induced premature shutoff of viral and cellular protein synthesis and was slightly growth restricted in cells of neural lineage (SK-N-SH human neuroblastoma cells) but was wild type for these two parameters in cells of nonneural lineage (immortalized primate Vero cells). Of particular interest was the observation that L/ST-4BS exhibited cell-type-specific expression of both the gamma(1)34.5 transcripts and the latency-associated transcripts (LATs). Thus, expression of these transcripts was barely detectable in cells of neural lineage (NB41A3 mouse neuroblastoma cells) but was wild type in Vero cells. In vivo, L/ST-4BS was reactivated from mouse trigeminal ganglia with reduced efficiency and delayed kinetics relative to wild-type virus. L/ST-4BS was completely attenuated for neurovirulence (LD50 > 10(6) PFU) relative to wild-type virus (LD50 < 900 PFU), although the four single-base-pair substitutions lie outside the coding region for the neurovirulence factor, ICP34.5. Collectively, the complex in vitro and in vivo phenotypes of L/ST-4BS can be attributed to (i) disruptions of the ICP4 binding site in the L/ST promoter and subsequent overexpression of the L/STs and OPP; (ii) alterations in ORF-O, which is also mutated in L/ST-4BS; or (iii) alterations in other cryptic genes or cis-acting elements.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9557715      PMCID: PMC109655          DOI: 10.1128/JVI.72.5.4250-4264.1998

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

1.  Detection of specific sequences among DNA fragments separated by gel electrophoresis.

Authors:  E M Southern
Journal:  J Mol Biol       Date:  1975-11-05       Impact factor: 5.469

2.  The terminal a sequence of the herpes simplex virus genome contains the promoter of a gene located in the repeat sequences of the L component.

Authors:  J Chou; B Roizman
Journal:  J Virol       Date:  1986-02       Impact factor: 5.103

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Rapid and efficient site-specific mutagenesis without phenotypic selection.

Authors:  T A Kunkel
Journal:  Proc Natl Acad Sci U S A       Date:  1985-01       Impact factor: 11.205

5.  Monoclonal antibodies to herpes simplex virus type 1 proteins, including the immediate-early protein ICP 4.

Authors:  S D Showalter; M Zweig; B Hampar
Journal:  Infect Immun       Date:  1981-12       Impact factor: 3.441

6.  Method for induction of mutations in physically defined regions of the herpes simplex virus genome.

Authors:  R M Sandri-Goldin; M Levine; J C Glorioso
Journal:  J Virol       Date:  1981-04       Impact factor: 5.103

7.  Activities of herpes simplex virus type 1 (HSV-1) ICP4 genes specifying nonsense peptides.

Authors:  N A DeLuca; P A Schaffer
Journal:  Nucleic Acids Res       Date:  1987-06-11       Impact factor: 16.971

8.  Identification by antibody to a synthetic peptide of a protein specified by a diploid gene located in the terminal repeats of the L component of herpes simplex virus genome.

Authors:  M Ackermann; J Chou; M Sarmiento; R A Lerner; B Roizman
Journal:  J Virol       Date:  1986-06       Impact factor: 5.103

9.  Characterization of herpes simplex virus 1 alpha proteins 0, 4, and 27 with monoclonal antibodies.

Authors:  M Ackermann; D K Braun; L Pereira; B Roizman
Journal:  J Virol       Date:  1984-10       Impact factor: 5.103

10.  Herpes simplex virus type 1 ICP27 is an essential regulatory protein.

Authors:  W R Sacks; C C Greene; D P Aschman; P A Schaffer
Journal:  J Virol       Date:  1985-09       Impact factor: 5.103

View more
  24 in total

1.  Neither LAT nor open reading frame P mutations increase expression of spliced or intron-containing ICP0 transcripts in mouse ganglia latently infected with herpes simplex virus.

Authors:  Shun-Hua Chen; Lily Yeh Lee; David A Garber; Priscilla A Schaffer; David M Knipe; Donald M Coen
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

Review 2.  Peculiarities of herpes simplex virus (HSV) transcription: an overview.

Authors:  Július Rajcáni; Vojvodová Andrea; Rezuchová Ingeborg
Journal:  Virus Genes       Date:  2004-04       Impact factor: 2.332

3.  Attenuation of herpes simplex virus neurovirulence with picornavirus cis-acting genetic elements.

Authors:  Stephanie A Campbell; Matthew Mulvey; Ian Mohr; Matthias Gromeier
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

4.  Transient expression of herpes simplex virus type 1 ICP22 represses viral promoter activity and complements the replication of an ICP22 null virus.

Authors:  J Jason Bowman; Joseph S Orlando; David J Davido; Anna S Kushnir; Priscilla A Schaffer
Journal:  J Virol       Date:  2009-06-17       Impact factor: 5.103

5.  Noninvasive bioluminescence imaging of herpes simplex virus type 1 infection and therapy in living mice.

Authors:  Gary D Luker; J Patrick Bardill; Julie L Prior; Christina M Pica; David Piwnica-Worms; David A Leib
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

Review 6.  Overview of Alternaria alternata Membrane Proteins.

Authors:  Ruyi Wang; Peng Zhao; Xizhen Ge; Pingfang Tian
Journal:  Indian J Microbiol       Date:  2020-04-22       Impact factor: 2.461

7.  Herpes simplex virus 2 expresses a novel form of ICP34.5, a major viral neurovirulence factor, through regulated alternative splicing.

Authors:  Shuang Tang; Nini Guo; Amita Patel; Philip R Krause
Journal:  J Virol       Date:  2013-03-13       Impact factor: 5.103

8.  Origin of expression of the herpes simplex virus type 1 protein U(S)1.5.

Authors:  J Jason Bowman; Priscilla A Schaffer
Journal:  J Virol       Date:  2009-07-01       Impact factor: 5.103

9.  MicroRNAs expressed by herpes simplex virus 1 during latent infection regulate viral mRNAs.

Authors:  Jennifer Lin Umbach; Martha F Kramer; Igor Jurak; Heather W Karnowski; Donald M Coen; Bryan R Cullen
Journal:  Nature       Date:  2008-07-02       Impact factor: 49.962

10.  ICP0 antagonizes ICP4-dependent silencing of the herpes simplex virus ICP0 gene.

Authors:  Mingyu Liu; Brandon Rakowski; Edward Gershburg; Carla M Weisend; Olivier Lucas; Edward E Schmidt; William P Halford
Journal:  PLoS One       Date:  2010-01-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.